Two Sigma Investments’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-201,558
Closed -$5.41M 3133
2022
Q1
$5.41M Buy
201,558
+190,569
+1,734% +$6.4M 0.02% 882
2021
Q4
$524K Sell
10,989
-17,992
-62% -$804K ﹤0.01% 3210
2021
Q3
$1.93M Sell
28,981
-116,799
-80% -$8.32M ﹤0.01% 2031
2021
Q2
$11.4M Sell
145,780
-42,924
-23% -$3.17M 0.03% 723
2021
Q1
$17.9M Buy
188,704
+100,159
+113% +$11.9M 0.05% 484
2020
Q4
$10.8M Buy
88,545
+38,523
+77% +$4.22M 0.03% 564
2020
Q3
$4.37M Sell
50,022
-30,903
-38% -$2.15M 0.02% 860
2020
Q2
$5.23M Buy
+80,925
New +$4.67M 0.03% 628

Other funds holding TPTX

Two Sigma Investments's TPTX Position: Q2 2022 in Review

Two Sigma Investments sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2022, closing a stake of 201,558 shares — an estimated $5.41M sold.

Two Sigma Investments first reported a position in TPTX in Q2 2020 and held it in 8 quarters. The position peaked at $17.9M in Q1 2021. 208 funds tracked by Wall St. Rank hold TPTX as of Q2 2022.

  • Two Sigma Investments reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Two Sigma Investments sold 201,558 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $5.41M.
  • Two Sigma Investments first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2020 and held it in 8 quarters.
  • Two Sigma Investments's Turning Point Therapeutics, Inc. Common Stock position peaked at $17.9M in Q1 2021.
  • 208 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Two Sigma Investments's 13F filing for Q2 2022, filed 15 Aug 2022.